Signal Transduction and Chemical Biology Research Program
The pathways that send chemical signals from the cell surface to the nucleus are major targets of genotype-driven therapies for cancer. The Signal Transduction and Chemical Biology Research Program aims to better understand how changes in tumor cells alter these signaling networks, and to identify—or create—molecules that target these pathways as potential new therapies for cancer.
The Signal Transduction and Chemical Biology Research Program is organized into four groups with common research interests:
Cell Cycle Control
Identifying how changes in key cell cycle proteins help tumor cells escape the typical response of cell death and lead to uncontrollable growth
Finding and developing compounds that inhibit key drivers of cancer formation
Combining ‘big data’ experimental approaches to understand the changes in signaling networks that drive cancer formation
Stem Cell Biology
Determining how cancer-initiating stem cells continuously renew and seed distant sites to promote metastasis, and understanding the role of these cells in resistance to chemotherapies
Meet the Program Members
The Signal Transduction and Chemical Biology program, led by Ian Macara, Ph.D., and Stephen Fesik, Ph.D., is an active group of more than 40 basic, translational, and clinical scientists whose goal is to understand how signaling networks control cell proliferation and function, to identify drug leads, and to develop new cancer therapeutics.
APC Inhibits Ligand-Independent Wnt Signaling by the Clathrin Endocytic Pathway.
Saito-Diaz K, Benchabane H, Tiwari A, Tian A, Li B (CE), Thompson JJ, Hyde AS, Sawyer LM, Jodoin JN, Santos E, Lee LA, Coffey RJ (GI), Beauchamp RD (GI), Williams CS (GI), Kenworthy AK, Robbins DJ, Ahmed Y, Lee E (GI, ST).
Dev. Cell 2018 MAR 12 44(5):566-581.e8 PMC5884143
Targeting extracellular matrix stiffness to attenuate disease: From molecular mechanisms to clinical trials.
Lampi MC, Reinhart-King CA (ST).
Sci Transl Med 2018 JAN 3 10(422) PMID:29298864
The Plk1 Piece of the Nuclear Envelope Disassembly Puzzle
Dawson TR, Wente SR (ST)
Dev. Cell 2017 OCT 23 43(2):115-117 PMID:29065301
Chronicle of a Neuronal Death Foretold: Preventing Aging by Keeping MGRN1 at the Nucleus
Ortolano NA, Gama VL (ST)
Mol. Cell 2017 MAY 4 66(3):301-303 PMID:28475865
Myelin Avoids the JAM.
Follis RM, Carter BD (ST).
Neuron 2016 AUG 17 91(4):713-6 PMID:27537479.
Head of the Class: OLIG2 and Glioblastoma Phenotype.
Leelatian N, Ihrie RA (ST).
Cancer Cell 2016 MAY 9 29(5):613-5 PMID:27165737
Kaiso is required for MTG16-dependent effects on colitis-associated carcinoma.
Short, S.P., Barrett, C.W., Stengel, K.R., Revetta, F.L., Choksi, Y.A., Coburn, L.A., Lintel, M.K., McDonough, E.M., Washington, M.K. (GI), Wilson, K.T. (GI), Prokhortchouk, E., Chen, X., Hiebert, S.W. (ST), Reynolds, A.B. (GI) & Williams, C.S. (GI).
Oncogene 38(25):5091-5106, 2019; PMC6586520.